In some NSCLC patients, mainly adenocarcinoma, molecular alterations in driver genes, like EGFR, KRAS, HER2, ALK, MET, BRAF, RET,ROS1, and NTRK are recognized. This evidence concerns the gene KRAS and non-small cell lung carcinoma.